The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Vitale C, Griggio V, Todaro M, et al. Magic pills: new oral drugs to treat chronic lymphocytic leukemia. Expert Opin Pharmacother. 2017 Mar;18(4):411–425.
   PubMed Web of Science ®Google Scholar
• Burger JA, O’Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018 Aug;15(8):510–527.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018 Dec 27;379(26):2517–2528.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 Mar 22;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432–443.
   PubMed Web of Science ®Google Scholar
• Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):43–56.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311–322.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768–778.
   PubMed Web of Science ®Google Scholar
• Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 Jan;19(1):65–75.
   PubMed Web of Science ®Google Scholar
• Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 Apr 12;131(15):1704–1711.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001 Apr 15;19(8):2153–2164.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15;19(8):2165–2170.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164–1174.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 Apr 1;28(10):1756–1765.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Thijssen R, Slinger E, Weller K, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015 Aug;100(8):e302–6.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Advani RH, Kahl BS, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015 Sep;170(5):669–678.
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826–2833.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb;18(2):230–240.
   PubMed Web of Science ®Google Scholar
• Brander DM, Seymour JF, Kipps TJ, et al. Durability of responses on continuous therapy and following drug cessation with venetoclax and rituximab: long-term follow-up analysis of a phase 1b study in patients with relapsed CLL. Blood. 2019;134(Supplement_1):3036.
   Google Scholar
• Kater AP, Seymour JF, Hillmen P, et al. Fixed Duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase iii study. J Clin Oncol. 2019 Feb 1;37(4):269–277.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst BF, et al. Four-year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):355.
   Google Scholar
• Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year progression-free and overall survival in CLL. Blood. 2016 Dec 15;128(24):2770-2773.
   Web of Science ®Google Scholar
• EMA. Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies: European Medicine Agency. 25 November 2016. [cited 2020 Apr 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/12/WC500179047.pdf
   Google Scholar
• Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018 May 24;131(21):2357–2366.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for Patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
   Google Scholar
• Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017 Jun 22;129(25):3362–3370.
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Eyre TA, et al. venetoclax as monotherapy or in combination: patterns of use and predictors of outcomes in an international multicenter study of CLL patients. Blood. 2018;132(Supplement 1):3142.
   Google Scholar
• Roberts AW, Ma S, Kipps TJ, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 Jul 11;134(2):111–122.
   PubMed Web of Science ®Google Scholar
• Wu J, Bolen C, Seymour JF, et al. Impact of major genomic alterations on outcome of relapsed/refractory chronic lymphocytic leukemia patients receiving venetoclax plus rituximab in the phase 3 MURANO study. Hematol Oncol. 2019;37(S2):106–108.
   Google Scholar
• Soumerai JD, Ni A, Darif M, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul;6(7):e366–e374.
   PubMed Web of Science ®Google Scholar
• Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 7;133(10):1011–1019.
   PubMed Web of Science ®Google Scholar
• Lew TE, Anderson MA, Lin VS, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv. 2020 Jan 14;4(1):165–173.
   PubMed Web of Science ®Google Scholar
• Freise KJ, Jones AK, Menon RM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017 Dec;35(4):679–684.
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Eyre TA, et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019 May 28;3(10):1568–1573.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v78–84.
   PubMed Web of Science ®Google Scholar
• Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017 May 1;28(5):1050–1056.
   PubMed Web of Science ®Google Scholar
• Brown JR, Davids MS, Chang J, et al. Outcomes of ibrutinib therapy given after prior venetoclax therapy in ibrutinib-naïve patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood. 2018;132(Supplement 1):5556.
   Google Scholar
• Mato AR, Roeker LE, Eyre TA, et al. Efficacy of therapies following venetoclax discontinuation in CLL: focus on B-Cell receptor signal transduction inhibitors and cellular therapies. Blood. 2019;134(Supplement_1):502.
   Google Scholar
• Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 Jun 27;133(26):2765–2775.
   PubMed Web of Science ®Google Scholar
• Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019 Jun 6;380(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res off J Am Assoc Cancer Res. 2015 Aug 15;21(16):3705–3715.
   PubMed Web of Science ®Google Scholar
• Deng J, Isik E, Fernandes SM, et al. Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 Oct;31(10):2075–2084.
   PubMed Web of Science ®Google Scholar
• Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095–2103.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: the CLARITY Study. J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.
   Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018 Oct 11;132(15):1568–1572.
   PubMed Web of Science ®Google Scholar
• Rogers KA, Huang Y, Stark A, et al. Initial results of the phase 2 treatment naive cohort in a phase 1b/2 Study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia. Blood. 2017;130(Supplement 1):431.
   Google Scholar
• Rogers KA, Huang Y, Ruppert AS, et al. Phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Blood. 2018;132(Supplement 1):693.
   Google Scholar
• Lampson BL, Tyekucheva S, Crombie JL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):32.
   Google Scholar
• Brown JR, Eichhorst BF, Ghia P, et al. A phase 3 trial comparing the efficacy and safety of acalabrutinib in combination with venetoclax with or without obinutuzumab, compared with investigator’s choice of chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL) without Del(17p) or TP53 mutation. Blood. 2019;134(Supplement_1):4318.
   Google Scholar
• Kersting S, Levin M-D, Niemann CU, et al. First line treatment with venetoclax and ibrutinib induction followed by obinutuzumab intensification exclusively in CLL/SLL patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial). Blood. 2019;134(Supplement_1):1753.
   Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014 Jun 12;370(24):2286–2294.
   PubMed Web of Science ®Google Scholar
• Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val Mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019 Mar;9(3):342–353.
   PubMed Web of Science ®Google Scholar
• Tausch E, Close W, Dolnik A, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019 Sep;104(9):e434–e437.
   PubMed Web of Science ®Google Scholar
• Weiss J, Peifer M, Herling CD, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.). Haematologica. 2019 Nov;104(11):e540.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan S, Chyla B, Mensing S, et al. Sustained minimal residual disease negativity predicted in chronic lymphocytic leukemia patients treated with venetoclax combination therapy for 2 years: an integrated mechanistic analysis of multiple phase I and II studies. Blood. 2017;130(Supplement 1):4318.
   Google Scholar
• Ujjani CS, Roeker LE, Shadman M, et al. Veneto-STOP study: sequential assessment of minimal residual disease by next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients. Blood. 2019;134(Supplement_1):1758.
   Google Scholar